Back to results
US 2023/0144192 A1Published application
Treatment of osteogenesis imperfecta
AssigneeGenzyme Corporation
InventorsPanteleimon D. MAVROUDIS, Nikhil PILLAI, Qingping WANG
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for treating and improving b1osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of an agent that binds and neutralizes transforming growth factor beta (TGF-β).
Claims21
A method for treating osteogenesis imperfecta (OI) in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-TGF-β antibody,
- wherein the antibody comprises heavy chain complementarity-determining regions (CDRs) 1-3 comprising SEQ ID NOs:4-6, respectively, light chain CDR1-3 comprising SEQ ID NOs:7-9, respectively, wherein the antibody comprises a human IgG4 constant region having a proline at position 228 (Eu numbering), and
- wherein the therapeutic effective amount is
- 1 to 8 mg/kg, optionally 2, 2.5, or 5 mg/kg, administered bi-annually, or 0.1 to 1 mg/kg, optionally 0.35, 0.4, or 0.5 mg/kg, administered every 3 months (Q3M).
Dependencies are inferred from the claim text.